Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
The U.S. Supreme Court is poised to rule in a case with the potential to limit where patent owners can file infringement suits, but experts say the ruling may not significantly alter the landscape for drug patent litigation.
Drug patent litigators said the outcome of the TC Heartland LLC v. Kraft Foods Group Brands LLC case may not wind up dramatically affecting where drug patent cases under the Hatch-Waxman Act are filed. They spoke at the American Conference Institute’s 11th Annual Paragraph IV Disputes conference in New York April 24.
The impact of how the high court rules in TC Heartland is probably more important for general patent cases than Hatch-Waxman cases, Nicolas P. Barzoukas, of Reed Smith LLP in Houston, told conference attendees.
The high court heard oral arguments in the case in late March ( TC Heartland LLC v. Kraft Foods Group Brands LLC, U.S., No. 16-341, argued 3/27/17 ).
In the high court case, the justices are considering whether the U.S. Court of Appeals for the Federal Circuit’s broad interpretation of venue statutes—permitting patent infringement suits to be brought in almost any federal district court—is correct.
TC Heartland appealed the Federal Circuit’s April 2016 ruling to the Supreme Court, arguing a narrower concept of venue should apply. TC Heartland wants venue limited to where the defendant is incorporated or where the defendant has committed infringing acts and has a regular place of business.
But conference panelists said even if the high court applies a more restrictive interpretation of venue, it may not significantly affect Hatch-Waxman practice. Currently, patent holders bring the bulk of infringement suits over generic drug companies’ abbreviated new drug applications in federal district courts in Delaware and New Jersey.
“The biggest driver in this is risk,” John J. Molenda, with Steptoe & Johnson LLC in New York, told the group. “If a generic could craft a strategy to transfer venue, does it necessarily want to?”
“The folks in Delaware and New Jersey know a lot about patent law,” Molenda said. “It may be better to be with the devil you know than the devil you don’t know,” he said.
“There is some comfort in dealing with the venues the parties already know,” Barzoukas agreed.
In addition, because of the timing issues in abbreviated new drug application cases resulting from the Hatch-Waxman Act’s automatic 30-month stay provision, it’s helpful to have a judge who’s familiar with these types of cases, Lisa Jakob, legal director of intellectual property litigation at Merck & Co. in Rahway, N.J., said.
Under the Hatch-Waxman Act, an automatic 30-month stay on regulatory approval is triggered when a branded drugmaker sues a generic drugmaker over its filing of an abbreviated new drug application seeking FDA approval to make a generic version of the branded drug.
“The sophistication of the forum benefits everyone,” Jakob said.
And even if TC Heartland’s position is adopted, it’s far from guaranteed that generic companies will move to transfer venue, Paul A. Ainsworth, of Sterne Kessler Goldstein & Fox LLP, said.
“A lot of things go into the decision of whether to transfer,” he said, including whether there are other related cases pending in the patentee’s chosen forum.
An important consideration for generic companies, Molenda said, is cost. “Do you want to get into a costly fight over jurisdiction and venue?”
“I think it’s very company dependent,” Barzoukas said. “Some will consent to the plaintiff’s choice of venue and some will spend a lot of money to fight jurisdiction because it’s worth it to them.”
“For some companies, they want to maintain some control over where they’re sued,” Ainsworth said.
For example, Mylan Inc. has moved to transfer venue to federal court in West Virginia on the grounds it’s incorporated there and has lots of employees there.
But Mylan is unusual in that regard.
“It’s very hard for other companies to establish the home court advantage Mylan has,” Molenda said. It will be business as usual for most other companies, he added.
And even if the high court winds up narrowing venue in the TC Heartland case, if multiple related ANDA suits are pending in multiple jurisdictions, they could wind up being consolidated into multidistrict litigation anyway, the speakers said.
No one on the panel was willing to place wagers on whether the high court would adopt a broader or a more restrictive interpretation of the venue statutes.
“It’s a little difficult to do much tea leaf reading here,” Steven M. Coyle of Cantor Colburn LLP, who moderated the panel, said, observing the justices’ questions at oral argument went in both directions.
Bradford J. (Jim) Badke, of Sidley Austin LLP in New York, also participated on the panel.
To contact the reporter on this story: Dana A. Elfin in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Brian Broderick at email@example.com
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)